Ajay Major, Assistant Professor of Medicine at the University of Colorado School of Medicine, shared a post on X about a recent abstract by Arnaud Amzallag, Scientific Associate Director at Bristol Myers Squibb:
“Golcadomide (CELMoD) plus R-CHOP first line LBCL.
- Randomized 0.2 vs 0.4 mg in dose expansion
- 1-yr PFS 85% at 0.4 mg (77% at 0.2)
- 90% EOT MRD- at 0.4 (73% at 0.2)
- better EOT MRD- with 0.4 mg across high-risk genetics
GOLSEEK-1 RCT ongoing with 0.4 mg dose.”
Authors: Arnaud Amzallag, Tara Basavanhally, Jason Westin, Anita Gandhi, Mark Kaplan, et al.
More posts featuring Ajay Major.
Ajay Major is an Assistant Professor of Medicine at the University of Colorado School of Medicine, specializing in lymphoma and CLL/SLL. He is the Founder and President of Pager Publications, as well as the Founder and Editor-in-Chief of in-House. Additionally, he serves as a Reviewer for the Bellevue Literary Review.